ORION ANNOUNCES THE
ORION ANNOUNCES THE RAPID LEAD OPTIMIZATION OF OB-004 - A CCR2 ANTAGONIST
30 nov. 2021 10h07 HE | Orion Biotechnology Canada Ltd.
Ottawa, Ontario, Canada, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of  G Protein-Coupled Receptors (GPCRs) with a novel drug...